Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lerong Li

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The American Journal of Clinical Nutrition|January 22, 2016
Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trialsYan Zheng, Uta Ceglarek, Tao Huang, et al.
Cancer Letters|January 28, 2017
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitorsMing Zhang, Ratnakar Singh, Shaohua Peng, et al.
Oncotarget|July 8, 2016
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutationsYuehong Wang, Ratnakar Singh, Liguang Wang, et al.
Oncotarget|November 22, 2017
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell linesNene N Kalu, Tuhina Mazumdar, Shaohua Peng, et al.
The Journal of Biological Chemistry|September 5, 2021
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancersJayanthi P Gudikote, Tina Cascone, Alissa Poteete, et al.
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2015
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung CancerRenata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Cancer Discovery|February 20, 2019
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerTriparna Sen, B Leticia Rodriguez, Limo Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLCVincent K Lam, Jianjun Zhang, Carol C Wu, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The American Journal of Clinical Nutrition|January 22, 2016
Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trialsYan Zheng, Uta Ceglarek, Tao Huang, et al.
Cancer Letters|January 28, 2017
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitorsMing Zhang, Ratnakar Singh, Shaohua Peng, et al.
Oncotarget|July 8, 2016
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutationsYuehong Wang, Ratnakar Singh, Liguang Wang, et al.
Oncotarget|November 22, 2017
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell linesNene N Kalu, Tuhina Mazumdar, Shaohua Peng, et al.
The Journal of Biological Chemistry|September 5, 2021
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancersJayanthi P Gudikote, Tina Cascone, Alissa Poteete, et al.
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2015
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung CancerRenata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Cancer Discovery|February 20, 2019
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerTriparna Sen, B Leticia Rodriguez, Limo Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLCVincent K Lam, Jianjun Zhang, Carol C Wu, et al.
Pageof 3